Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + tobemstomig
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
nab-paclitaxel + tobemstomig is an investigational combination therapy consisting of nab-paclitaxel, a nanoparticle albumin-bound formulation of the chemotherapy agent paclitaxel, and tobemstomig, a novel immunotherapy. Nab-paclitaxel acts as an antineoplastic agent by stabilizing microtubules and inhibiting cell division in cancer cells. Tobemstomig is a bispecific monoclonal antibody targeting PD-1 and TIM-3 immune checkpoints, designed to enhance anti-tumor immune responses by blocking inhibitory signals on T cells. This combination aims to leverage the cytotoxic effects of chemotherapy with the immune activation provided by checkpoint inhibition for synergistic anti-cancer activity.
- Other names
- RG6139RG-6139RG 6139RO7121661RO-7121661RO 7121661
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + tobemstomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + tobemstomig.